High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 601–700 of 1,000
Bhutani, D., Zonder, J. A., Valent, J. N., Tageja, N., Ayash, L. J., Deol, A., Al-Kadhimi, Z. S., Abrams, J., Lum, L. G., Ratanatharathorn, V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1808-5 · Cited by 29
“ASCT continues to retain importance in the treatment of MM and can improve progression-free survival as well as overall survival [6, 7].”
Blanes, M., de la Rubia, J., Lahuerta, J. J., González, J. D., Ribas, P., Solano, C., Alegre, A. M., & Sanz, M. Á. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802630170 · Cited by 29
“ASCT is considered the standard of care for patients with MM up to 65 years of age [1,2], but despite encouraging results, most patients relapse after transplantation.”
BackgroundBjörkstrand, B., & Gahrton, G. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.08.010 · Cited by 28
Ungerstedt, J. S., Watz, E., Uttervall, K., Johansson, B.-M., Wahlin, B. E., Näsman, P., Ljungman, P. T., Gruber, A., Nygell, U. A., & Nahi, H. (2011) · Medical Oncology · doi:10.1007/s12032-011-0029-3 · Cited by 32
Role of autologous stem-cell transplantation in multiple myeloma
Attal, M., & Harousseau, J. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.09.006 · Cited by 30
Outpatient high‐dose melphalan in multiple myeloma patients
Kassar, M., Medoff, E., Seropian, S., & COOPER, D. L. (2006) · Transfusion · doi:10.1111/j.1537-2995.2007.01073.x · Cited by 30
Myeloma – new approaches to combined nephrological–haematological management
Haubitz, M., & Peest, D. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi318 · Cited by 33
“In a second trial, the median progression-free survival was 32 vs 20 months and the median overall survival 54 vs 42 months [ 20 ].”
BackgroundJung, S.-H., Ahn, S.-Y., Choi, H.-W., Shin, M.-G., Lee, S.-S., Yang, D.-H., Ahn, J.-S., Kim, Y.-K., Kim, H.-J., & Lee, J.-J. (2017) · Blood Research · doi:10.5045/br.2017.52.4.293 · Cited by 27
“Subsequent randomized trials demonstrated improved response rates and survival among patients treated with HDT/ASCT in comparison to those treated with conventional chemotherapy [28, 29].”
Alexander, E. T., Towery, J. A., Miller, A. N., Kramer, C., Hogan, K. R., Squires, J. E., Stuart, R. K., & Costa, L. J. (2011) · Transfusion · doi:10.1111/j.1537-2995.2011.03085.x · Cited by 32
Autologous Stem Cell Transplantation and Multiple Myeloma Cancer Stem Cells
Matsui, W. H., Borrello, I., & Mitsiades, C. S. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.036 · Cited by 29
Poudyal, B. S., Tuladhar, S. M., Neupane, S., Sapkota, S., Pandit, S., Shrestha, P. R., Poudel, B., Bajaracharya, M., Sweiss, K. I., Patel, P. R., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.02.011 · Cited by 27
Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis
Hou, Z., Jiang, P., Su, S., & Zhou, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1003228 · Cited by 29
Hematopoietic Stem Cell Transplantation: Implications for Critical Care Nurses
Saria, M. G., & Gosselin-Acomb, T. K. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.53-63 · Cited by 27
Berenson, J. R., Yellin, O., Woytowitz, D., Flam, M. S., Cartmell, A., Patel, R., Duvivier, H., Nassir, Y., Eades, B., Abaya, C. D., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01244.x · Cited by 27
“High-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) has shown a survival advantage over conventional chemotherapy in some studies (3, 4); although other trials have not shown a survival advantage with HDT-ASCT for patients responding to primary induction therapy (5).”
ResultYhim, H.-Y., Kım, K., Kim, J. S., Kang, H. J., Kim, J.-A., Min, C.-K., Bae, S. H., Park, E., Yang, D.-H., Suh, C., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.164 · Cited by 28
Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2236 · Cited by 27
Cure of multiple myeloma – more hype, less reality
Hari, P., Pasquini, M. C., & Vesole, D. H. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705194 · Cited by 32
Hatjiharissi, E., Terpos, E., Papaioannou, M., Hatjileontis, C., Kaloutsi, V. D., Galaktidou, G., Gerotziafas, G., Christakis, J. I., & Zervas, K. (2004) · Hematological Oncology · doi:10.1002/hon.738 · Cited by 32
“The median survival from diagnosis is approximately 3–4 years.(2,3) Thalidomide has shown a significant anti-myeloma activity in both refractory/relapsed and newly diagnosed MM patients.”
BackgroundMehta, J., & Singhal, S. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705799 · Cited by 29
Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!
Hajifathali, A., Parkhideh, S., Kazemi, M. H., Chegeni, R., Roshandel, E., & Gholizadeh, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29769 · Cited by 26
“Although autologous transplantation is a standard treatment for MM, relapse is still one of the major post‐transplant problems in this disease (Attal et al., 1996; Child et al., 2003; Martinez‐Lopez et al., 2011).”
BackgroundChen, X., Luo, X., Zu, Y., Issa, H. A., Li, L., Ye, H., Yang, T., Hu, J., & Wei, L. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23416 · Cited by 26
“Age (years), median (range) 60 (24-85) 61 (37-85) 60 (24-85) .”
Λαζανά, Ι., Flóró, L., Christmas, T., Shah, S., Bramham, K., Cuthill, K., Bassett, P., Schey, S., Kazmi, M. A., Potter, V. T., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01657-y · Cited by 27
Li, W., Wang, Y., Song, Y., Xu, L., Zhao, J., & Fang, B. (2015) · Oncology Letters · doi:10.3892/ol.2015.2946 · Cited by 27
Ballestrero, A., Boy, D., Gonella, R., Miglino, M., Clavio, M., Barbero, V., Nencioni, A., Gobbi, M., & Patrone, F. (2007) · Annals of Hematology · doi:10.1007/s00277-007-0366-7 · Cited by 26
Ford, P., Grant, S. J., Mick, R., & Keck, G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9912 · Cited by 26
Shaughnessy, P. J., Chao, N. J. A., Shapiro, J., Walters, K., McCarty, J. M., Abhyankar, S., Shayani, S., Helmons, P. J., Leather, H. L., Pazzalia, A., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.05.008 · Cited by 29
Lisenko, K., Sauer, S., Bruckner, T. M., Egerer, G., Goldschmidt, H., Hillengaß, J., Schmier, J. W., Shah, S., Witzens‐Harig, M., Ho, A. D., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3137-4 · Cited by 29
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 30
Shah, E. E., Young, R. P., Wong, S. W. K., Damon, L. E., Wolf, J. L., Shah, N. D., Leavitt, A. D., Loeffler, P., & Martin, T. G. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.024 · Cited by 26
Libby, E. N., Garcia, D. A., Quintana, D. D., Fekrazad, M. H., Bauman, J. E., Ebaid, A., Hromas, R., Rabinowitz, I., & Wiggins, C. L. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.897700 · Cited by 26
Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell Lines
Boegsted, M., Holst, J. M., Fogd, K., Falgreen, S., Sørensen, S., Schmitz, A., Bukh, A., Johnsen, H. E., Nyegaard, M., & Dybkær, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019322 · Cited by 34
“Since the 1990s, melphalan has been used in high dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) [1] and has as such improved the response rate, as well as prolonged event free survival (EFS) and overall survival (OS) [2].”
BackgroundSmith, V. R., Popat, U., Ciurea, S. O., Nieto, Y. L., Anderlini, P. N., Rondón, G., Alousi, A. M., Qazilbash, M. H., Kebriaei, P., Khouri, I. F., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23499 · Cited by 25
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
Bensinger, W., Rotta, M., Storer, B. E., Chauncey, T. R., Holmberg, L., Becker, P. S., Sandmaier, B. M., Storb, R. F., & Maloney, D. G. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.1 · Cited by 27
LEADING ARTICLE International uniform response criteria for multiple myeloma
Durie, B., Harousseau, J., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K. C., Gertz, M. A., Dimopoulos, M. A., Westin, J., Sonneveld, P., et al. (2006) · Cited by 25
Self-citationHigh-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis
Sanchorawala, V. (2020) · Acta Haematologica · doi:10.1159/000506498 · Cited by 25
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01371-1 · Cited by 27
“ASCT is an effective treatment for patients with MM and has been associated with both PFS and OS benefit [3, 6, 14].”
BackgroundSchwestermann, J., Bešše, A., Driessen, C., & Bešše, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.899272 · Cited by 27
Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor
Göker, H., Etgül, S., & Büyükaşık, Y. (2015) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2015.05.011 · Cited by 25
Liu, Z., Qi, X. L., Xj, W., Luo, C., & Lu, Y. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800535 · Cited by 25
Preliminary dosimetric evaluation of 166 Ho-TTHMP for human based on biodistribution data in rats
Yousefnia, H., Zolghadri, S., Jalilian, A. R., Tajik, M., & Ghannadi‐Maragheh, M. (2014) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2014.08.017 · Cited by 25
Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7900 · Cited by 26
Parmar, S., Bookout, R., Shapiro, J., Tombleson, R. L., Perkins, J., Kim, J., Yue, B., Tomblyn, M., Alsina, M., & Nishihori, T. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.56 · Cited by 25
Kazmi, S. M. A., Saliba, R. M., Donato, M. L., Wang, M., Hosing, C. M., Qureshi, S. R., Anderlini, P. N., Popat, U., Champlin, R. E., Giralt, S., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.160 · Cited by 26
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 27
Multiple myeloma: Experience of an institute in limited resource setting
Jacob, L. A., Babu, M., Lakshmaiah, K. C., Babu, K. G., Lokanatha, D., Rajeev, L. K., Lokesh, K. N., Rudresha, A. H., Agarwal, A., & Garg, S. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_87_17 · Cited by 25
Rosenberg, A. S., Brunson, A. M., Jonas, B. A., Keegan, T. H. M., & Wun, T. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy073 · Cited by 25
Crees, Z. D., Stockerl-Goldstein, K. E., Vainstein, A., Chen, H., & DiPersio, J. F. (2019) · Future Oncology · doi:10.2217/fon-2019-0380 · Cited by 26
Frontline therapy for newly diagnosed patients with multiple myeloma
Jung, S., Jo, J., Song, G., Ahn, S., Yang, D., Ahn, J., Kim, H., & Lee, J. (2020) · Blood Research · doi:10.5045/br.2020.s007 · Cited by 25
“Subsequent randomized trials have also shown that HDT/ASCT, compare to conventional chemotherapy, improved response rates and survival [6, 23].”
BackgroundThe potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma
Altenburg, J. D., & Farag, S. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.993753 · Cited by 28
“While high-dose chemotherapy with stem cell support increases the proportion of complete responses, the effect on prolongation of overall survival remains relatively modest, and all patients invariably relapse [1,4-7].”
BackgroundMorris, T. C. M., Kettle, P. J., Drake, M. B., Jones, F. G. C., Hull, D. R., Boyd, K. D., Morrison, A. A., Clarke, P. A., O’Reilly, P., & Quinn, J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07360.x · Cited by 25
“Despite these improvements myeloma remains incurable with a median survival in the order of 30–36 months except for younger, fitter patients who, if treated with autologous transplantation, have a median survival in the order of 5 years (Attal et al, 1996; Child et al, 2004).”
BackgroundNakasone, H., Kanda, Y., Ueda, T., Matsumoto, K., Shimizu, N., Minami, J., Sakai, R., Hagihara, M., Yokota, A., Oshima, K., et al. (2009) · American Journal of Hematology · doi:10.1002/ajh.21552 · Cited by 28
“Although the progression of myeloma is unavoidable after ASCT, both progression-free survival (PFS) and quality of life have been significantly improved [1–5].”
BackgroundFirstline Treatment and Maintenance in Newly Diagnosed Multiple Myeloma Patients
Roussel, M., Facon, T. T. F., Moreau, P., Harousseau, J., & Attal, M. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_9 · Cited by 29
Maclachlan, K. H., Came, N. A., Diamond, B. T., Roshal, M., Ho, C., Thoren, K. L., Mayerhoefer, M. E., Landgren, O., & Harrison, S. J. (2021) · Pathology · doi:10.1016/j.pathol.2021.02.003 · Cited by 24
Roussel, M., Lauwers‐Cancès, V., Macro, M., Leleu, X. P., Royer, B., Hulin, C., Karlin, L., Perrot, A., Touzeau, C., Chrétien, M., et al. (2022) · Blood · doi:10.1182/blood.2021014635 · Cited by 28
Ozaki, S., & Shimizu, K. (2014) · BioMed Research International · doi:10.1155/2014/394792 · Cited by 25
Role of thalidomide in the treatment of patients with multiple myeloma
Morgan, G. J., & Davies, F. E. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.012 · Cited by 24
“[4] Child JA, Morgan GJ, Davies FE, et al.”
BackgroundSelf-citationTokuda, Y., Tajima, T., Narabayashi, M., Takeyama, K., Watanabe, T., Fukutomi, T., Chou, T., Sano, M., Igarashi, T., Sasaki, Y., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00639.x · Cited by 24
Castellani, M., Carletto, M., Baldini, L., Calori, R., Longari, V., Soligo, D. A., Dellavedova, L., & Gerundini, P. (2009) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3181c3619c · Cited by 24
Tenneti, P., Zahid, U., Iftikhar, A., Yun, S., Sohail, A., Warraich, Z., & Anwer, F. (2018) · Sarcoma · doi:10.1155/2018/2640674 · Cited by 24
Mian, H. S., Mian, O., Rochwerg, B. N., Foley, R., & Wildes, T. M. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.05.014 · Cited by 25
Goswami, C., Poonia, S., Kumar, L., & Sengupta, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00633 · Cited by 28
“A number of randomized (22) and non-randomized trials, meta-analyses, and population-based studies have provided evidence in favor of the efficacy of this regime, measured in terms of high response rates, improved OS and PFS (17, 23).”
BackgroundAn update on drug combinations for treatment of myeloma
Srikanth, M., Davies, F. E., & Morgan, G. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.1.1 · Cited by 24
“For older, less fit patients unsuitable for ASCT, a major goal is the maximisation of response rates and the depth of responses, which have been suggested to translate into improved PFS and OS.”
BackgroundResultSelf-citationBruno, B., Sorasio, R., Patriarca, F. F., Montefusco, V., Guidi, S., Busca, A., Scimè, R., Console, G., Milone, G., Marotta, G., et al. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00816.x · Cited by 24
Zou, Y., Sheng, Z., Niu, S., Wang, H., Yu, J., & Xu, J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.774393 · Cited by 24
Stem-cell transplantation in multiple myeloma: how far have we come?
Soekojo, C. Y., & Kumar, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719888111 · Cited by 27
Role of Stem Cell Transplantation
Harousseau, J. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.001 · Cited by 30
An elective single autograft with high-dose melphalan: single-center study of 451 patients
Sirohi, B., Powles, R., Mehta, J., Rudin, C. M., Kulkarni, S., Horton, C., Saso, R. M., Singhal, S., & Treleaven, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705000 · Cited by 24
A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise
Tian, M., Xing, R., Guan, J., Yang, B., Zhao, X. S., Yang, J., Zhan, C., & Zhang, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01201 · Cited by 23
Kumar, S. K., Mikhael, J., LaPlant, B. R., Lacy, M. Q., Buadi, F. K., Dingli, D., Gertz, M. A., Laumann, K. M., Miceli, T. S., Mahlman, M., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.175 · Cited by 24
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT
Kumar, S. K., Dingli, D., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.24 · Cited by 23
Vela‐Ojeda, J., Esparza, M. A. G.-R., Padilla-González, Y., Gómez‐Almaguer, D., Gutiérrez‐Aguirre, C. H., Gómez-Rangel, D., Morales‐Toquero, A., Ruiz‐Delgado, G. J., Delgado‐Lamas, J. L., & Ruiz-Argüelles, G. J. (2007) · Annals of Hematology · doi:10.1007/s00277-006-0235-9 · Cited by 23
“There are several randomized clinical trials that show better outcome and survival benefit using high-dose therapy and autologous hematopoietic stem cell transplantation (HSCT) when compared with chemotherapy [3, 8].”
BackgroundCancer stem cells—clinical relevance
Jones, R. J. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0534-4 · Cited by 23
“Even the most intensive therapy for myeloma, blood or marrow transplantation [17, 18], provided no overall survival advantage in the national intergroup trial [19] or in two recent metaanalyses [20, 21].”
BackgroundAutologous hematopoietic cell transplantation: An update for clinicians
Hamadani, M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.952662 · Cited by 27
Bhatt, V. R., Loberiza, F. R., Jing, H., Bociek, R. G., Bierman, P. J., Maness, L. J., Vose, J. M., Armitage, J. O., & Akhtari, M. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.024 · Cited by 25
Stettler, J., Novak, U., Baerlocher, G. M., Seipel, K., Taleghani, B. M., & Pabst, T. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1233542 · Cited by 25
“Since the late 1990s, high-dose melphalan treatment (200mg/m2) followed by autologous stem cell transplantation (ASCT) has been regarded as a standard procedure for younger MM patients in the absence of relevant comorbidities [3-5].”
BackgroundDiagnosis and management of neuropathies associated with plasma cell dyscrasias
E, E. R. P., Marks, D. K., & Raza, S. (2017) · Hematological Oncology · doi:10.1002/hon.2417 · Cited by 23
The Paraprotein - an Enduring Biomarker.
Tate, J. R. (2019) · Europe PMC (PubMed Central) · Cited by 47
Brown, S., Pawlyn, C., Tillotson, A., Sherratt, D., Flanagan, L. M., Low, E., Morgan, G. J., Williams, C. D., Kaiser, M., Davies, F. E., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.11.019 · Cited by 23
Self-citationBergin, K., Wellard, C. J., Moore, E., McQuilten, Z., Blacklock, H. A., Harrison, S. J., Ho, P. J., King, T., Quach, H., Mollee, P. N., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.01.016 · Cited by 23
Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
Stokes, J., Molina, M. S., Hoffman, E. A., Simpson, R. J., & Katsanis, E. (2021) · Cancers · doi:10.3390/cancers13071702 · Cited by 24
Using Genomics to Identify High-Risk Myeloma after Autologous Stem Cell Transplantation
Shaughnessy, J. D., & Barlogie, B. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.10.002 · Cited by 23
Abidi, M. H., Agarwal, R., Tageja, N., Ayash, L. J., Deol, A., Al-Kadhimi, Z. S., Abrams, J., Cronin, S. M., Ventimiglia, M., Lum, L. G., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.003 · Cited by 23
“INTRODUCTION High-dose chemotherapy followed by autologous stem cell transplant (ASCT) has shown improved progression-free survival and reduced overall mortality compared to conventional chemotherapy in patients with multiple myeloma (MM) [1-5].”
BackgroundQiao, S.-K., Guo, X., Ren, J., & Ren, H. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.156134 · Cited by 28
Advances in biology and treatment of multiple myeloma
Ludwig, H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi717 · Cited by 23
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Fonseca, R., & Stewart, A. K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0620 · Cited by 26
“This is based on the observations that this treatment approach results in improvement in overall survival and disease progression (9, 68).”
MethodPalumbo, A., Avonto, I., Bruno, B., Falcone, A. P., Scalzulli, P. R., Ambrosini, M. T., Bringhen, S., Gay, F., Rus, C., Cavallo, F., et al. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.028 · Cited by 23
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Sanchorawala, V., Hoering, A., Seldin, D. C., Finn, K. T., Fennessey, S. A., Sexton, R. E., Mattar, B. I., Safah, H. F., Holmberg, L., Dean, R. M., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.98 · Cited by 22
Nishihori, T., Alekshun, T. J., Shain, K. H., Sullivan, D. M., Baz, R., Perez, L. E., Pidala, J., Kharfan‐Dabaja, M. A., Ochoa-Bayona, J. L., Fernandez, H. F., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09099.x · Cited by 22
“The role of high-dose chemotherapy followed by autologous haematopoietic cell transplantation (HCT) has been established (Attal et al, 1996; Child et al, 2003; Koreth et al, 2007; Kumar et al, 2009).”
BackgroundWu, X., Shi, J., Wu, Y., Yi, T., Hou, J., Meng, X., Hu, X., Han, Y., Jiang, W., Tang, S., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.11.13669 · Cited by 22
Kumar, L., Ghosh, J., Ganessan, P., Gupta, A., Hariprasad, R., & Kochupillai, V. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.343 · Cited by 22
Kumar, S. K., Dingli, D., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07069.x · Cited by 22
“(Attal et al, 1996; Child et al, 2003; Fermand et al, 2005).”
BackgroundKobbe, G., Bruns, I., Schroeder, T. A., Czibere, A. G., Warnecke, J., Hieronimus, N., Safaian, N., Kondakci, M., Saure, C., Germing, U., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq059 · Cited by 22
“High-dose therapy (HDT) and autologous blood stem-cell transplantation (ASCT) is the treatment of choice for patients <65 years with multiple myeloma (MM) because it prolongs disease-free survival and overall survival in comparison with conventional chemotherapy [1, 2].”
BackgroundBortezomib and lenalidomide as front-line therapy for multiple myeloma
Zou, Y., Lin, M., Sheng, Z., & Niu, S. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.847935 · Cited by 23
Sirohi, B., Powles, R., Lawrence, D., Treleaven, J., Kulkarni, S., Leary, A. F., Rudin, C. M., Horton, C., & Morgan, G. J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm180 · Cited by 25
“However, it is also increasingly clear that myeloma patients with a median survival in excess of 5 years and with good quality of life (QoL), require all of the above drugs in treatment packages in sequence, in addition to standard treatments such as infusional chemotherapy and autografting [9–11].”
BackgroundSelf-citationMultiple Myeloma in the Very Old: An IASIA Conference Report
Tuchman, S. A., Shapiro, G. R., Ershler, W. B., Badros, A. Z., Cohen, H. J., Dispenzieri, A. A., Flores, I. Q., Kanapuru, B., Jurivich, D. A., Longo, D. L., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju067 · Cited by 22
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
Meyers, D. E., Thakur, S. S., Thirukkumaran, C. M., & Morris, D. G. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0020-0 · Cited by 24
Connect MM Registry as a national reference for United States multiple myeloma patients
Ailawadhi, S., Jagannath, S., Narang, M., Rifkin, R. M., Terebelo, H. R., TOOMEY, K. E., Durie, B. G. M., Hardin, J. W., Gasparetto, C., Wagner, L. I., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2656 · Cited by 22
Current and Novel Alkylators in Multiple Myeloma
Schjesvold, F. H., & Oriol, A. (2021) · Cancers · doi:10.3390/cancers13102465 · Cited by 26
“Therapy with melphalan plus prednisone (MP) was the standard of care for patients with newly diagnose MM for almost 40 years [6,12] and when alternative combinations were developed as induction therapy for individuals eligible for high-dose melphalan therapy with hematopoietic stem-cell transplantation [8,13], it rema…”
BackgroundStay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy
Wolfson, B., Franks, S. E., & Hodge, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050509 · Cited by 22
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.